Sage Therapeutics Inc

+1.29 (+1.86%)
Earnings Announcements

Sage Therapeutics Announces First Quarter 2021 Financial Results

Published: 05/04/2021 11:13 GMT
Sage Therapeutics Inc (SAGE) - Qtrly Loss per Share $1.64.
Anticipates Cash, Cash Equivalents, and Marketable Securities of More Than $1.7 Billion at End of 2021.
Does Not Anticipate Receipt of Any Milestone Payments From Collaborations in 2021.
Q1 Earnings per Share View $-1.91 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.01 Million
Adjusted EPS is expected to be -$1.67

Next Quarter Revenue Guidance is expected to be $2.47 Million
Next Quarter EPS Guidance is expected to be -$1.75

More details on our Analysts Page.